Shared and unique imaging-derived endo-phenotypes of two typical antidepressant-applicative depressive patients
Creators
- 1. Child Development and Learning Science, Key Laboratory of Ministry of Education, Nanjing (China)
- 2. School of Biological Science & Medical Engineering, Southeast University, No. 2 Sipailou, Nanjing, 210096, Jiangsu Province (China)
- 3. Nanjing Brain Hospital, Medical School of Nanjing University, 210093, Nanjing (China)
- 4. Department of Psychiatry, the Affiliated Brain Hospital of Nanjing Medical University, 210029, Nanjing (China)
Description
Determining the clinical homogeneous and heterogeneous sets among depressive patients is the key to facilitate individual-level treatment decision. The diffusion tensor imaging (DTI) data of 62 patients with major depressive disorder (MDD) and 39 healthy controls were used to construct a Latent Dirichlet Allocation (LDA) Bayesian model. Another 48 MDD patients were used to verify the robustness. The LDA model was employed to identify both shared and unique imaging-derived factors of two typically antidepressant-targeted depressive patients, selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs). Furthermore, we applied canonical correlation analysis (CCA) between each factor loading and Hamilton depression rating scale (HAMD) sub-score, to explore the potential neurophysiological significance of each factor. The results revealed the imaging-derived connectional fingerprint of all patients could be situated along three latent factor dimensions; such results were also verified by the out-of-sample dataset. Factor 1, uniquely expressed by SNRI-targeted patients, was associated with retardation (r = 0.4, p = 0.037) and characterized by coupling patterns between default mode network and cognitive control network. Factor 3, uniquely expressed by SSRI-targeted patients, was associated with cognitive impairment (r = 0.36, p = 0.047) and characterized by coupling patterns within cognitive control and attention network, and the connectivity between threat and reward network. Shared factor 2, characterized by coupling patterns within default mode network, was associated with anxiety (r = 0.54, p = 0.005) and sleep disturbance (r = 0.37, p = 0.032). Our findings suggested that quantification of both homogeneity and heterogeneity within MDD may have the potential to inform rational design of pharmacological therapies. The shared and unique manifestations guiding pharmacotherapy of depressive patients are caused by the homogeneity and heterogeneity of underlying structural connections of the brain. Both shared and unique factor loadings were found in different antidepressant-targeted patients. Significant correlations between factor loading and HAMD sub-scores were found.
Availability note (English)
Available from: http://dx.doi.org/10.1007/s00330-022-09004-xAdditional details
Identifiers
Publishing Information
- Journal Title
- European Radiology (Internet)
- Journal Volume
- 33
- Journal Issue
- 1
- Journal Page Range
- p. 645-655
- ISSN
- 1432-1084
- CODEN
- EURAE3
INIS
- Country of Publication
- Germany
- Country of Input or Organization
- Germany
- INIS RN
- 54015700
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- ANTIDEPRESSANTS; BRAIN; CHEMOTHERAPY; CORRELATIONS; DATA COMPILATION; DECISION MAKING; DIFFUSION; DIRICHLET PROBLEM; IMAGE PROCESSING; NMR IMAGING; NORADRENALINE; PHENOTYPE; RELAXATION TIME; SEROTONIN; SLEEP; TENSORS; WEIGHTING FUNCTIONS
- Descriptors DEC
- ADRENAL HORMONES; AMINES; AROMATICS; AUTONOMIC NERVOUS SYSTEM AGENTS; AZAARENES; AZOLES; BODY; BOUNDARY-VALUE PROBLEMS; CARDIOTONICS; CARDIOVASCULAR AGENTS; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM AGENTS; DATA; DATA PROCESSING; DIAGNOSTIC TECHNIQUES; DRUGS; FUNCTIONS; HETEROCYCLIC COMPOUNDS; HORMONES; HYDROCARBONS; HYDROXY COMPOUNDS; INDOLES; INFORMATION; MEDICINE; NERVOUS SYSTEM; NEUROREGULATORS; ORGANIC COMPOUNDS; ORGANIC NITROGEN COMPOUNDS; ORGANS; PROCESSING; PSYCHOTROPIC DRUGS; PYRROLES; RADIOPROTECTIVE SUBSTANCES; RESPONSE MODIFYING FACTORS; SYMPATHOMIMETICS; THERAPY; TRYPTAMINES